The experimental 5-HT1A receptor agonist and D2 receptor antagonist was not effective on primary or secondary endpoints More: Newron drops development of sarizotan in Rett syndrome Source: News
read moreBCC marks the second non-melanoma skin cancer for which Libtayo has demonstrated first-in-class data, the firms note More: Sanofi/Regeneron's Libtayo shows benefit in BCC Source: News
read moreThe Billion Molecules against Covid19 Grand Challenge aims to screen billions of molecules with blocking interactions on SARS-CoV-2 More: JEDI launches billion molecules agains COVID19 challenge Source: News
read moreThe charity’s Centre for Drug Development will sponsor and fund a future Phase I clinical trial for CB213 More: Crescendo links with CRUK to progress cancer therapy Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals